Interferon alpha delivery systems for the treatment of hepatitis C

International Journal of Pharmaceutics

Volumn 369, Issue 1-2, 2009, Pages 121-135

  Thitinan, Sumalee ^a   McConville, Jason T ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

ADME; Hepatitis C; Liposomes; Microspheres; Oral drug delivery; Pegylation

Indexed keywords

5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; ALBINTERFERON ALPHA2B; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN1 INTERFERON; ATORVASTATIN; BOCEPREVIR; CASTANOSPERMINE 6 BUTYRATE; CONSENSUS INTERFERON; CPG 10101; ETANERCEPT; FLUINDOSTATIN; ISIS 14803; LOCTERON; MEDUSA INTERFERON; MERIMEPODIB; MEVINOLIN; MICROSPHERE; MULTIFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; SIMVASTATIN; TARIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE;

ABSENCE OF SIDE EFFECTS; ANTIVIRAL ACTIVITY; ANXIETY; APPETITE DISORDER; AREA UNDER THE CURVE; BIOLOGICAL ACTIVITY; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED RELEASE FORMULATION; DEPRESSION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG IMPLANTATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ERADICATION THERAPY; FATIGUE; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INSOMNIA; IRRITABILITY; LIVER CIRRHOSIS; MALAISE; MEMORY DISORDER; MENTAL INSTABILITY; MONOTHERAPY; MYALGIA; NEUTROPENIA; PHYSICAL CHEMISTRY; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR BINDING; REVIEW; SIDE EFFECT; SUSTAINED DRUG RELEASE; TARGET ORGAN; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIVIRAL AGENTS; CONTINENTAL POPULATION GROUPS; DELAYED-ACTION PREPARATIONS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; ETHNIC GROUPS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA;

EID: 60849098417     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.11.027     Document Type: Review

References (115)

1. Ahmed, A., Keeffe, E.B., 1999. Overview of interferon therapy for chronic hepatitis C. http://www.mdconsult.com.proxy-hs.researchport.umd.edu/das/article/body/87704338-2/jorg=journal&source=&sp=11811305&sid=0/N/275480/1.html?issn=1089-3261 (accessed 01/02/08).
2. Alberti A. Interferon alfacon-1-a novel interferon for the treatment of chronic hepatitis C. Biodrugs 12 (1999) 343-357
3. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F.X., Moyer L.A., Kaslow R.A., and Margolis H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341 (1999) 556-562
4. Alter, M.J., Margolis, H.S., Bell, B.P., 1998. Recommendations for prevention and control of hepatitis C virus infection and HCV-related chronic disease. http://www.cdc.gov/mmwr/preview/mmwrhtml/00055154.htm (accessed 10/01/08).
5. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., and Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 144 (2006) 705-714
6. Backer D.E. PEGylated interferons. Rev. Gastroenterol. Disord. 1 (2001) 87-99
7. Badkar A.V., Smith A.M., Eppstein J.A., and Banga A.K. Transdermal delivery of interferon alpha-2B using microporation and iontophoresis in hairless rats. Pharm. Res. 24 (2007) 1389-1395
8. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., Ehrlich G.K., Pan W., Xu Z.X., Modi M.W., Farid A., and Berthold W. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem. 12 (2001) 195-202
9. Bain V.G., Kaita K.D., Yoshida E.M., Swain M.G., Heathcote E.J., Neumann A.U., Fiscella M., Yu R., Osborn B.L., Cronin P.W., Freimuth W.W., McHutchison J.G., and Subramanian G.M. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J. Hepatol. 44 (2006) 671-678
10. Balan V., Nelson D.R., Sulkowski M.S., Everson G.T., Lambiase L.R., Wiesner R.H., Dickson R.C., Post A.B., Redfield R.R., Davis G.L., Neumann A.U., Osborn B.L., Freimuth W.W., and Subramanian G.M. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir. Ther. 11 (2006) 35-45
11. Barazani Y., Hiatt J.R., Tong M.J., and Busuttil R.W. Chronic viral hepatitis and hepatocellular carcinoma. World J. Surg. 31 (2007) 1243-1248
12. Bechet A., Verrijk R., Humphries J., Venneker E., and de Leede L. Pharmacokinetics, safety and biomarkers in man after administration of Locteron, a once every two-weeks controlled release formulation of interferon-alpha. J. Hepatol. 44 (2006) S210-S1210
13. Bethesda M.D. AHFS Drug Information, Electronic version (2007), American Society of Health-System Pharmacists
14. Blatt L.M., Mutchnick M.G., Tong M.J., Klion F.M., Lebovics E., Freilich B., Bach N., Smith C., Herrera J., Tobias H., Conrad A., Schmid P., and McHutchison J.G. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J. Viral Hepat. 7 (2000) 196-202
15. Bonacini M., Groshen S., Yu M.C., Govindarajan S., and Lindsay K.L. Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles County. AM. J. Gastroenterol. 96 (2001) 2438-2441
16. ®: a polymer-based sustained release technology for protein and peptide drugs. Expert Opin. Drug Deliv. 4 (2007) 441-451
17. Davis G.L. Monitoring of viral levels during therapy of hepatitis C. Hepatology 36 (2002) S145-S151
18. Davis G.L., Krawczynski K., and Szabo G. Hepatitis C virus infection-pathobiology and implications for new therapeutic options. Digest. Dis. Sci. 52 (2007) 857-875
19. Diwan M., and Park T.G. Stabilization of recombinant interferon-alpha by pegylation for encapsulation in PLGA microspheres. Int. J. Pharm. 252 (2003) 111-122
20. ®: a long-lasting and orally available single-amino acid mutant of interferon alpha. J. Interferon Cytokine Res. 27 (2007) 709-1709
21. Dumont J.A., Low S.C., Peters R.T., and Bitonti A.J. Monomeric Fc fusions-impact on pharmacokinetic and biological activity of protein therapeutics. Biodrugs 20 (2006) 151-160
22. Durand F. Hepatitis C and liver transplantation. Gastroenterol. Clin. Biol. 26 (2002) B82-B90
23. Dzyublyk I., Yegorova T., Moroz L., Popavych E., Zaytsev I., Miroshnichenko V., Hermann E., Zeuzem S., van Hoogdalem E.J., and Humphries J.E. Phase 2a study to evaluate the safety and tolerability and anti-viral of 4 doses of a novel, controlled-release interferon-alfa 2b (Locteron) given every 2 weeks for 12 weeks in treatment-naive patients with chronic hepatitis C (genotype 1). Hepatology 46 (2007) 863A-864A
24. El-Serag H.B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36 (2002) S74-S83
25. Eppstein D.A., and Stewart W.E. Altered pharmacological properties of liposome-associated human interferon-alpha. J. Virol. 41 (1982) 575-582
26. Farrell G.C., Bacon B.R., and Goldin R.D. Lymphoblastoid interferon Alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon Alfa-2b: Results of an international randomized controlled trial. Hepatology 27 (1998) 1121-1127
27. Franciscus, A., 2004. Review of HCV, HBV and HIV/HCV coinfection related news and highlights. http://www.hcvadvocate.org/news/NewsUpdates_pdf/News_Review_2004/NewsRev-41.pdf (accessed 02/02/08).
28. Franciscus, A., 2008. Hepatitis C treatments in current clinical development. http://www.hcvadvocate.org/hepatitis/hepC/HCVDrugs.html (accessed 01/02/08).
29. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 36 (2002) S237-S244
30. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347 (2002) 975-982
31. Friedrich-Rust M., Zeuzem S., and Sarrazin C. Current therapy for hepatitis C. Int. J. Colorectal Dis. 22 (2007) 341-349
32. Fujioka K., Takada Y., Sato S., and Miyata T. Long-acting delivery system of interferon-IFN minipellet. J. Control. Release 33 (1995) 317-323
33. Fujioka K., Takada Y., Sato S., and Miyata T. Novel delivery system for proteins using collagen as a carrier material-the minipellet. J. Control. Release 33 (1995) 307-315
34. Garson J.A., Uhnoo I., Whitby K., Braconier J.H., Deaville R., Duberg A., Wallmark E., Wistrom J., Goldin R.D., and Spacey B. Virological, biochemical and histological effects of human lymphoblastoid interferon in Swedish patients with chronic hepatitis C. J. Viral Hepat. 4 (1997) 325-331
35. Gilbert, C.W., Park-Cho, M., 1997. U.S. Patent No. 5,951,974. Interferon polymer conjugates.
36. Glue P., Fang J.W.S., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S.K., Salfi M., and Jacobs S. Pegylated interferon-alpha 2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther. 68 (2000) 556-567
37. Grace M., Youngster S., Gitlin G., Sydor W., Xie L., Westreich L., Jacobs S., Brassard D., Bausch J., and Bordens R. Structural and biologic characterization of pegylated recombinant IFN-alpha 2b. J. Interferon Cytokine Res. 21 (2001) 1103-1115
38. Gregoriadis G., Jain S., Papaioannou I., and Laing P. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int. J. Pharm. 300 (2005) 125-130
39. Hadziyannis S.J., Sette H.J., Morgan T.R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer H.J., Bernstein D., Rizzetto M., Zeuzem S., Pockros P.J., Lin A., and Ackrill A.M. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Int. Med. 140 (2004) 346-355
40. Harris J.M., Martin N.E., and Modi M. Pegylation-a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40 (2001) 539-551
41. Heathcote E.J., Shiffman M.L., Cooksley W.G.E., Dusheiko G.M., Lee S.S., Balart L., Reindollar R., Reddy R.K., Wright T.L., Lin A., Hoffman J., and De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343 (2000) 1673-1680
42. Herrmann S., Mohl S., Siepmann F., Siepmann J., and Winter G. New insight into the role of polyethylene glycol acting as protein release modifier in lipidic implants. Pharm. Res. 24 (2007) 1527-1537
43. Herrmann S., Winter G., Mohl S., Siepmann F., and Siepmann J. Mechanisms controlling protein release from lipidic implants: effects of PEG addition. J. Control. Release 118 (2007) 161-168
44. Hirst D.H., Jain S., Laing P., Genkin D., and Gregoriadis G. Preparation and properties of polysialylated interferon α-2b. AAPS Annual Meeting. Toronto, Canada (2002) M1056
45. Howell S.B. Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam™ technology. Cancer J. 7 (2001) 219-227
46. Hoyumpa A., Sharkey F.E., Brock P.S., Page R.T., Brock P.S., Kashi M.R., Herrera A.M., Smith W., Poy I.G., Webb A.L., and Ali O. Greater prevalence of cirrhosis in Hispanics than in Caucasians or African Americans. Hepatology 42 (2005) 442A
47. Hoyumpa A.M., Stockus A.V., Page R.T., and Herrera A.M. Hepatitis C in a predominantly Hispanic population. Hepatology 36 (2002) 557A
48. Hugle T., and Cerny A. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Rev. Med. Virol. 13 (2003) 361-371
49. Ikeda M., Abe K., Yamada M., Dansako H., Naka K., and Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44 (2006) 117-125
50. Jo Y.W., Youn Y.S., Lee S.H., Kim B.M., Kang S.H., Yoo M., Choi E.C., and Lee K.C. Long-acting interferon-alpha-2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics. Int. J. Pharm. 309 (2006) 87-93
51. Kajihara M., Sugie T., Hojo T., Maeda H., Maeda H., Sano A., Fujioka K., Sugawara S., and Urabe Y. Development of a new drug delivery system for protein drugs using silicone (II). J. Control. Release 73 (2001) 279-291
52. Kajihara M., Sugie T., Mizuno M., Tamura N., Sano A., Fujioka K., Kashiwazaki Y., Yamaoka T., Sugawara S., and Urabe Y. Development of new drug delivery system for protein drugs using silicone (I). J. Control. Release 66 (2000) 49-61
53. Karau C., Petszulat M., and Schmidt P.C. Preparation and stability of interferon-alpha-containing liposomes. Int. J. Pharm. 128 (1996) 89-98
54. Kim W.R. Global epidemiology and burden of hepatitis C. Microbes Infect. 4 (2002) 1219-1225
55. Lepe R., Layden-Almer J.E., Layden T.J., and Cotler S. Ethnic differences in the presentation of chronic hepatitis C. J. Viral Hepat. 13 (2006) 116-120
56. Liang T.J., Rehermann B., Seeff L.B., and Hoofnagle J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132 (2000) 296-305
57. Lindsay K.L., Trepo C., Heintges T., Shiffman M.L., Gordon S.C., Hoefs J.C., Schiff E.R., Goodman Z.D., Laughlin M., Yao R.J., and Albrecht J.K. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34 (2001) 395-403
58. Lurie Y., Nevens F., Aprosina Z.G., Fedorova T.A., Kalinin A.V., Klimova E.A., Ilan Y., Maevskaya M.V., Warnes T.W., Yuschuk N.D., Hellstrand K., and Gehlsen K.R. A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C. J. Viral Hepat. 9 (2002) 346-353
59. Mangia A., Ricci G.L., Persico M., Minerva N., Carretta V., Bacca D., Cela M., Piattelli M., Annese M., Maio G., Conte D., Guadagnino V., Pazienza V., Festi D., Spirito F., and Andriulli A. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J. Viral Hepat. 12 (2005) 292-299
60. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M.H., and Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
61. Martin, P., 2006. Beyond the next generation of therapeutic proteins. http://www.biotech-online.com/uploads/tx_ttproducts/datasheet/beyond-the-next-generation-of-therapeutic-proteins.pdf (accessed 02/02/08).
62. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., and Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339 (1998) 1485-1492
63. Melian E.B., and Plosker G.L. Interferon alfacon-1-a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 61 (2001) 1661-1691
64. Mizushima Y., Ikoma T., Tanaka J., Hoshi K., Ishihara T., Ogawa Y., and Ueno A. Injectable porous hydroxyapatite microparticles as a new carrier for protein and lipophilic drugs. J. Control. Release 110 (2006) 260-265
65. Mohl S., and Winter G. Continuous release of rh-interferon alpha-2a from triglyceride matrices. J. Control. Release 97 (2004) 67-78
66. Mohl S., and Winter G. Continuous release of rh-interferon alpha-2a from triglyceride implants: storage stability of the dosage forms. Pharm. Dev. Technol. 11 (2006) 103-110
67. Murphy S.L. Deaths: Final Data for 1998 (2000), US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Natural Vital Statistics Reports, Hyattsville, MD pp. 1-105
68. ®) in a chronic hepatitis C patient resistant to preceding treatment approaches. Hepato-Gastroenterol. 51 (2004) 1476-1479
69. ®) after preceding interferon approaches in a chronic hepatitis C patient with thrombocytopenia. Scand. J. Infect. Dis. 36 (2004) 395-399
70. Nainan O.V., Alter M.J., Kruszon-Moran D., Gao F.X., Xia G.L., McQuillan G., and Margolis H.S. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 131 (2006) 478-484
71. Nguyen H.A., and Ho S.B. Natural history of chronic hepatitis C: identifying a window of opportunity for intervention. Dm-Dis. Mon. 47 (2001) 593-609
72. Osborn B.L., Olsen H.S., Nardelli B., Murray J.H., Zhou J.X.H., Garcia A., Moody G., Zaritskaya L.S., and Sung C. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 303 (2002) 540-548
73. Parfieniuk A., Jaroszewicz J., and Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J. Gastroenterol. 13 (2007) 5673-5681
74. Perry C.M., and Wilde M.I. Interferon-alpha-2a-a review of its use in chronic hepatitis C. Biodrugs 10 (1998) 65-89
75. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., and Albrecht J. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352 (1998) 1426-1432
76. Qiu J., Wei X.H., Geng F., Liu R., Zhang J.W., and Xu Y.H. Multivesicular liposome formulations for the sustained delivery of interferon alpha-2b. Acta Pharmacol. Sin. 26 (2005) 1395-1401
77. Radwanski E., Perentesis G., Jacobs S., Oden E., Affrime M., Symchowicz S., and Zampaglione N. Pharmacokinetics of interferon alpha-2b in healthy-volunteers. J. Clin. Pharmacol. 27 (1987) 432-435
78. Ramadori G., and Meier V. Hepatitis C virus infection: 10 years after the discovery of the virus. Eur. J. Gastroenterol. Hepat. 13 (2001) 465-471
79. Ramirez R., and Patricia de la Cruz G. The Hispanic Population in the United States: March 2002. Curr. Popul. Rep. (2003) 20-545
80. Ramon J., Saez V., Baez R., Aldana R., and Hardy E. PEGylated interferon-alpha 2b: a branched 40K polyethylene glycol derivative. Pharm. Res. 22 (2005) 1374-1386
81. Reddy K.R., Wright T.L., Pockros P.J., Shiffman M., Everson G., Reindollar R., Fried M.W., Purdum P.P., Jensen D., Smith C., Lee W.M., Boyer T.D., Lin A., Pedder S., and DePamphilis J. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33 (2001) 433-438
82. Rosen H.R. Hepatitis C in the liver transplant recipient: current understanding and treatment. Microbes Infect. 4 (2002) 1253-1258
83. Sanchez A., Tobio M., Gonzalez L., Fabra A., and Alonso M.J. Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur. J. Pharm. Sci. 18 (2003) 221-229
84. Scannell K.M., Willard C.C., and Seeff L.B. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002, June 10-12. Hepatology 36 (2002) S3-S20
85. Schenker S., Cutler D., Finch J., Tamburro C.H., Affrime M., Sabo R., and Bay M. Activity and tolerance of a continuous subcutaneous infusion of interferon-alpha 2b in patients with chronic hepatitis C. J. Interferon Cytokine Res. 17 (1997) 665-670
86. Shechter Y., Preciado-Patt L., Schreiber G., and Fridkin M. Prolonging the half-life of human interferon-alpha 2 in circulation: design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)(7)-interferon-alpha 2. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 1212-1217
87. Shepherd J., Brodin H., Cave C., Waugh N., Price A., and Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol. Asses. 8 (2004) 1-125
88. Shim C.K., and Kim S.R. Administration route dependent bioavailability of interferon-alpha and effect of bile-salts on the nasal absorption. Drug Dev. Ind. Pharm. 19 (1993) 1183-1199
89. Starokadomskyy P.L., and Dubey I.Y. New absorption promoter for the buccal delivery: Preparation and characterization of lysalbinic acid. Int. J. Pharm. 308 (2006) 149-154
90. Strader D.B., and Seeff L.B. The natural history of chronic hepatitis C infection. Eur. J. Gastroenterol. Hepat. 8 (1996) 324-328
91. Subramanian G.M., Fiscella M., Lamouse-Smith A., Zeuzem S., and McHutchison J.G. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat. Biotechnol. 25 (2007) 1411-1419
92. Suginoshita Y., Tabata Y., Matsumura T., Toda Y., Nabeshima M., Moriyasu F., Kada Y., and Chiba T. Liver targeting of human interferon-beta with pullulan based on metal coordination. J. Control. Release 83 (2002) 75-88
93. Sweetman S.E. The complete drug reference. Martindale, Electronic Version (2008), Pharmaceutical Press, London
94. Tabata Y., Matsui Y., Uno K., Sokawa Y., and Ikada Y. Simple mixing of IFN with a polysaccharide having high liver affinity enables IFN to target to the liver. J. Interferon Cytokine Res. 19 (1999) 287-292
95. Tan S.L., Pause A., Shi Y.U., and Sonenberg N. Hepatitis C therapeutics: current status and emerging strategies. Nat. Rev. Drug Discov. 1 (2002) 867-881
96. Tong M.J., Reddy K.R., Lee W.M., Pockros P.J., Hoefs J.C., Keeffe E.B., Hollinger F.B., Hathcote E.J., White H., Foust R.T., Jensen D.M., Krawitt E.L., Fromm H., Black M., Blatt L.M., Klein M., Lubina J., Bailey R., Bala K., Balart L., Bonkovsky H., Cassidy W., Craig J.R., Donovan J., Dusheiko G.M., Ehrinpreis M., Everson G., Feinman S., Hauser S., Hunter E., James S., Killenberg P., Lee S., vanLeeuwen D.J., Lesesne H., Lieberman H., Lissoos T., Lumeng L., Lyche K., Minuk G., Mullen K., Payne K.M., Pimstone N., Poterucha J., Rosenblate H., Shafritz D., Smith C., and Willems B. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepatology 26 (1997) 747-754
97. Trepo C., Meyrueix R., Maynard M., Rouzier R., Bourliere M., Donazzolo Y., Zarski J., and Kravtzoff R. Novel sustained release formulation of IFN alpha-2b improves tolerability and demonstrates potent viral load reduction in a phase I/II HCV clinical trial. J. Clin. Virol. 36 (2006) S24
98. Verma S., Bonacini M., Govindarajan S., Kanel G., Lindsay K.L., and Redeker A. More advanced hepatic fibrosis in Hispanics with chronic hepatitis C infection: Role of patient demographics, hepatic necroinflammation, and steatosis. AM. J. Gastroenterol. 101 (2006) 1817-1823
99. Vyas S.P., Rawat M., Rawat A., Mahor S., and Gupta P.N. Pegylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of interferon alpha. Drug Dev. Ind. Pharm. 32 (2006) 699-707
100. Wang Y.S., Youngster S., Grace M., Bausch J., Bordens R., and Wyss D.F. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliver. Rev. 54 (2002) 547-570
101. Wasley, A., Grytdal, S., Gallagher, K., 2008. Surveillance for acute viral hepatitis-United States, 2006. http://www.cdc.gov/hepatitis/Statistics.htm (accessed 01/10/08).
102. Wills R.J., Dennis S., Spiegel H.E., Gibson D.M., and Nadler P.I. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin. Pharmacol. Ther. 35 (1984) 722-727
103. Wu J., Nantz M.H., and Zern M.A. Targeting hepatocytes for drug and gene delivery: Emerging novel approaches and applications. Front. Biosci. 7 (2002) 717-725
104. Xi K.L., Tabata Y., Uno K., Yoshimoto M., Kishida T., Sokawa Y., and Ikada Y. Liver targeting of interferon through pullulan conjugation. Pharm. Res. 13 (1996) 1846-1850
105. Xu J.F., Tan L., Goodrum K.J., and Kieliszewski M.J. High-yields and extended serum half-life of human interferon alpha 2b expressed in tobacco cells as Arabinogalactan-protein fusions. Biotechnol. Bioeng. 97 (2007) 997-1008
106. Yamada K., Odomi M., Okada N., Fujita T., and Yamamoto A. Chitosan oligomers as potential and safe absorption enhancers for improving the pulmonary absorption of interferon-alpha in rats. J. Pharm. Sci. 94 (2005) 2432-2440
107. Yamagata Y., Iga K., and Ogawa Y. Novel sustained-release dosage forms of proteins using polyglycerol esters of fatty acids. J. Control. Release 63 (2000) 319-329
108. Yang L., Yang W.Z., Bi D.Z., and Zeng Q. A novel method to prepare highly encapsulated interferon-alpha-2b containing liposomes for intramuscular sustained release. Eur. J. Pharm. Biopharm. 64 (2006) 9-15
109. Yoon Y.H., and Yi H.Y. Liver cirrhosis and viral Hepatitis C infection mortality among Hispanic subgroups in the United Statesm 1999-2003: a multiple cause analysis. Alcohol Clin. Exp. Res. 30 (2006) 168A
110. Zein N.N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J. Hepatol. 42 (2005) 315-322
111. Zeuzem S., Feinman S.V., Rasenack J., Heathcote E.J., Lai M.Y., Gane E., O'Grady J., Reichen J., Diago M., Lin A., Hoffman J., and Brunda M.J. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343 (2000) 1666-1672
112. Zeuzem S., Hultcrantz R., Bourliere M., Goeser T., Marcellin P., Sanchez-Tapias J., Sarrazin C., Harvey J., Brass C., and Albrecht J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol. 40 (2004) 993-999
113. Zeuzem S., Teuber G., Naumann U., Berg T., Raedle J., Hartmann S., and Hopf U. Randomized, double-blind, placebo-controlled trial of interferon Alfa2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 32 (2000) 835-841
114. Zhang C., Ping Q.N., Ding Y., Cheng Y., and Shen J. Synthesis, characterization, and microsphere formation of galactosylated chitosan. J. Appl. Polym. Sci. 91 (2004) 659-665
115. Zhou S.B., Deng X.M., He S.Y., Li X.H., Jia W.X., Wei D.P., Zhang Z.R., and Ma J.H. Study on biodegradable microspheres containing recombinant interferon-alpha-2a. J. Pharm. Pharmacol. 54 (2002) 1287-1292